Medexus Pharmaceuticals (FRA:P731) EV-to-EBITDA : 5.44 (As of Dec. 15, 2024)

Medexus Pharmaceuticals EV-to-EBITDA Chart

Medexus Pharmaceuticals Annual Data
	Trend	Mar15	Mar16	Mar17	Mar18	Mar19	Mar20	Mar21	Mar22	Mar23	Mar24
EV-to-EBITDA		Get a 7-Day Free Trial					11.33	-9.34	6.48	5.50	3.83

Medexus Pharmaceuticals Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
EV-to-EBITDA	Get a 7-Day Free Trial															5.19	4.50	3.83	3.97	5.11

Competitive Comparison of Medexus Pharmaceuticals's EV-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Medexus Pharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Medexus Pharmaceuticals's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Medexus Pharmaceuticals's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Medexus Pharmaceuticals's EV-to-EBITDA falls into.

Medexus Pharmaceuticals EV-to-EBITDA Calculation

Medexus Pharmaceuticals's EV-to-EBITDA for today is calculated as:

Medexus Pharmaceuticals's current Enterprise Value is €82.38 Mil.
Medexus Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €15.13 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medexus Pharmaceuticals  (FRA:P731) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Medexus Pharmaceuticals's PE Ratio (TTM) for today is calculated as:

Medexus Pharmaceuticals's share price for today is €1.98.
Medexus Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.097.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?

Medexus Pharmaceuticals EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Medexus Pharmaceuticals's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Medexus Pharmaceuticals Business Description